Acurx Pharmaceuticals Return on Equity

Acurx Pharmaceuticals (ACXP) currently reports a ROE of -122139.81%. That is below the Healthcare sector average of 20.86%. Use the charts on this page to explore Acurx Pharmaceuticals's ROE history and peer comparisons.

Acurx Pharmaceuticals's ROE of -122139.81% is lower than the Healthcare sector average of 20.86%. That is roughly 585711.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Acurx Pharmaceuticals's current -122139.81% should be judged against Healthcare norms (sector average: 20.86%) and against ACXP's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -122139.81%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.86%. From there, open related valuation or income-statement pages for Acurx Pharmaceuticals, and consider following ACXP for alerts when major investors trade the stock.

Acurx Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows -122139.81% versus a sector average near 20.86%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ACXP with unrelated industries.